Hyperlipidemia is associated with altered levels of insulin-like growth factor-I
Previous studies revealed altered levels of the circulating insulin-like growth factor-I (IGF-I) and of its binding protein-3 (IGFBP-3) in subjects with coronary atherosclerosis, metabolic syndrome and premature atherosclerosis. Hyperlipidemia is a powerful risk factor of atherosclerosis. We expecte...
Gespeichert in:
| Veröffentlicht in: | Physiological research 2008-01, Vol.57 (6), p.919-925 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 925 |
|---|---|
| container_issue | 6 |
| container_start_page | 919 |
| container_title | Physiological research |
| container_volume | 57 |
| creator | Malík, J Stulc, T Wichterle, D Melenovský, V Chytilová, E Lacinová, Z Marek, J Ceska, R |
| description | Previous studies revealed altered levels of the circulating insulin-like growth factor-I (IGF-I) and of its binding protein-3 (IGFBP-3) in subjects with coronary atherosclerosis, metabolic syndrome and premature atherosclerosis. Hyperlipidemia is a powerful risk factor of atherosclerosis. We expected IGF-I and IGFBP-3 alterations in subjects with moderate/severe hyperlipidemia but without any clinical manifestation of atherosclerosis. Total IGF-I and IGFBP-3 were assessed in 56 patients with mixed hyperlipidemia (MHL; cholesterol >6.0 mmol/l, triglycerides >2.0 mmol/l), in 33 patients with isolated hypercholesterolemia (IHC; cholesterol >6.0 mmol/l, triglycerides |
| doi_str_mv | 10.33549/physiolres.931281 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66654709</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1645052701</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-4936b42d26b635b08be556a1931e30949b9beaac2e82d664fbdcda10fe261d7a3</originalsourceid><addsrcrecordid>eNpdkE1Lw0AQhhdRbK3-AQ8SPHhL3Y9kkz2KqC0U9KDnZZOd2K2bbNxNLP33LrZQcC7DwPMOMw9C1wTPGcszcd-vd8E46yHMBSO0JCdoSkpMUyEKdoqmuOQ0LTNcTtBFCBuMaYELdo4mEcopL_MpelvsevDW9EZDa1RiQqJCcLVRA-hka4Z1ouwAPg4WfsCGxDWJ6cJoTZda8wXJp3fbSDWqHpxPl5forFE2wNWhz9DH89P74yJdvb4sHx9Wac0KOqSZYLzKqKa84iyvcFlBnnNF4h_AsMhEJSpQqqZQUs151lS61orgBignulBshu72e3vvvkcIg2xNqMFa1YEbg-Sc51mBRQRv_4EbN_ou3iYpobEyRiNE91DtXQgeGtl70yq_kwTLP9nyKFvuZcfQzWHzWLWgj5GDXfYLfkl-Nw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212222432</pqid></control><display><type>article</type><title>Hyperlipidemia is associated with altered levels of insulin-like growth factor-I</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Malík, J ; Stulc, T ; Wichterle, D ; Melenovský, V ; Chytilová, E ; Lacinová, Z ; Marek, J ; Ceska, R</creator><creatorcontrib>Malík, J ; Stulc, T ; Wichterle, D ; Melenovský, V ; Chytilová, E ; Lacinová, Z ; Marek, J ; Ceska, R</creatorcontrib><description>Previous studies revealed altered levels of the circulating insulin-like growth factor-I (IGF-I) and of its binding protein-3 (IGFBP-3) in subjects with coronary atherosclerosis, metabolic syndrome and premature atherosclerosis. Hyperlipidemia is a powerful risk factor of atherosclerosis. We expected IGF-I and IGFBP-3 alterations in subjects with moderate/severe hyperlipidemia but without any clinical manifestation of atherosclerosis. Total IGF-I and IGFBP-3 were assessed in 56 patients with mixed hyperlipidemia (MHL; cholesterol >6.0 mmol/l, triglycerides >2.0 mmol/l), in 33 patients with isolated hypercholesterolemia (IHC; cholesterol >6.0 mmol/l, triglycerides <2.0 mmol/l), and in 29 healthy controls (cholesterol<6.0 mmol/l, triglycerides<2.0 mmol/l). The molar ratio of IGF-I/IGFBP-3 was used as a measure of free IGF-I. IHC subjects differed from controls by lower total IGF-I (164+/-60 vs. 209+/-73 ng/ml, p=0.01) and IGF-I /IGFBP-3 ratio (0.14+/-0.05 vs. 0.17+/-0.04, p=0.04). Compared to controls, MHL subjects had lower total IGF-I (153+/-54 ng/ml, p=0.0002) and IGFBP-3 (2.8+/-0.6 mg/ml, p<0.0001), but higher IGF-I/IGFBP-3 ratio (0.25+/-0.06, p<0.0001). Differences remained significant after the adjustment for clinical and biochemical covariates, except for triglycerides. Patients with both IHC and MHL have lower total IGF-I compared to controls. The mechanism is presumably different in IHC and MHL. Because of prominent reduction of IGFBP-3 in patients with MHL, they have reduced total IGF-I despite the actual elevation IGF-I/IGFBP-3 ratio as a surrogate of free IGF-I.</description><identifier>ISSN: 0862-8408</identifier><identifier>EISSN: 1802-9973</identifier><identifier>DOI: 10.33549/physiolres.931281</identifier><identifier>PMID: 18052685</identifier><language>eng</language><publisher>Czech Republic: Institute of Physiology</publisher><subject>Adult ; Biomarkers - blood ; Case-Control Studies ; Cholesterol - blood ; Conflicts of interest ; Correlation analysis ; Diet ; Female ; Growth hormones ; Humans ; Hypercholesterolemia - blood ; Hyperlipidemias - blood ; Independent sample ; Insulin-Like Growth Factor Binding Protein 3 ; Insulin-Like Growth Factor Binding Proteins - blood ; Insulin-Like Growth Factor I - analysis ; Lipoproteins, HDL - blood ; Lipoproteins, LDL - blood ; Male ; Metabolic syndrome ; Middle Aged ; Mortality ; Statistical methods ; Studies ; Triglycerides - blood</subject><ispartof>Physiological research, 2008-01, Vol.57 (6), p.919-925</ispartof><rights>Copyright Institute of Physiology 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-4936b42d26b635b08be556a1931e30949b9beaac2e82d664fbdcda10fe261d7a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,865,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18052685$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Malík, J</creatorcontrib><creatorcontrib>Stulc, T</creatorcontrib><creatorcontrib>Wichterle, D</creatorcontrib><creatorcontrib>Melenovský, V</creatorcontrib><creatorcontrib>Chytilová, E</creatorcontrib><creatorcontrib>Lacinová, Z</creatorcontrib><creatorcontrib>Marek, J</creatorcontrib><creatorcontrib>Ceska, R</creatorcontrib><title>Hyperlipidemia is associated with altered levels of insulin-like growth factor-I</title><title>Physiological research</title><addtitle>Physiol Res</addtitle><description>Previous studies revealed altered levels of the circulating insulin-like growth factor-I (IGF-I) and of its binding protein-3 (IGFBP-3) in subjects with coronary atherosclerosis, metabolic syndrome and premature atherosclerosis. Hyperlipidemia is a powerful risk factor of atherosclerosis. We expected IGF-I and IGFBP-3 alterations in subjects with moderate/severe hyperlipidemia but without any clinical manifestation of atherosclerosis. Total IGF-I and IGFBP-3 were assessed in 56 patients with mixed hyperlipidemia (MHL; cholesterol >6.0 mmol/l, triglycerides >2.0 mmol/l), in 33 patients with isolated hypercholesterolemia (IHC; cholesterol >6.0 mmol/l, triglycerides <2.0 mmol/l), and in 29 healthy controls (cholesterol<6.0 mmol/l, triglycerides<2.0 mmol/l). The molar ratio of IGF-I/IGFBP-3 was used as a measure of free IGF-I. IHC subjects differed from controls by lower total IGF-I (164+/-60 vs. 209+/-73 ng/ml, p=0.01) and IGF-I /IGFBP-3 ratio (0.14+/-0.05 vs. 0.17+/-0.04, p=0.04). Compared to controls, MHL subjects had lower total IGF-I (153+/-54 ng/ml, p=0.0002) and IGFBP-3 (2.8+/-0.6 mg/ml, p<0.0001), but higher IGF-I/IGFBP-3 ratio (0.25+/-0.06, p<0.0001). Differences remained significant after the adjustment for clinical and biochemical covariates, except for triglycerides. Patients with both IHC and MHL have lower total IGF-I compared to controls. The mechanism is presumably different in IHC and MHL. Because of prominent reduction of IGFBP-3 in patients with MHL, they have reduced total IGF-I despite the actual elevation IGF-I/IGFBP-3 ratio as a surrogate of free IGF-I.</description><subject>Adult</subject><subject>Biomarkers - blood</subject><subject>Case-Control Studies</subject><subject>Cholesterol - blood</subject><subject>Conflicts of interest</subject><subject>Correlation analysis</subject><subject>Diet</subject><subject>Female</subject><subject>Growth hormones</subject><subject>Humans</subject><subject>Hypercholesterolemia - blood</subject><subject>Hyperlipidemias - blood</subject><subject>Independent sample</subject><subject>Insulin-Like Growth Factor Binding Protein 3</subject><subject>Insulin-Like Growth Factor Binding Proteins - blood</subject><subject>Insulin-Like Growth Factor I - analysis</subject><subject>Lipoproteins, HDL - blood</subject><subject>Lipoproteins, LDL - blood</subject><subject>Male</subject><subject>Metabolic syndrome</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Statistical methods</subject><subject>Studies</subject><subject>Triglycerides - blood</subject><issn>0862-8408</issn><issn>1802-9973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkE1Lw0AQhhdRbK3-AQ8SPHhL3Y9kkz2KqC0U9KDnZZOd2K2bbNxNLP33LrZQcC7DwPMOMw9C1wTPGcszcd-vd8E46yHMBSO0JCdoSkpMUyEKdoqmuOQ0LTNcTtBFCBuMaYELdo4mEcopL_MpelvsevDW9EZDa1RiQqJCcLVRA-hka4Z1ouwAPg4WfsCGxDWJ6cJoTZda8wXJp3fbSDWqHpxPl5forFE2wNWhz9DH89P74yJdvb4sHx9Wac0KOqSZYLzKqKa84iyvcFlBnnNF4h_AsMhEJSpQqqZQUs151lS61orgBignulBshu72e3vvvkcIg2xNqMFa1YEbg-Sc51mBRQRv_4EbN_ou3iYpobEyRiNE91DtXQgeGtl70yq_kwTLP9nyKFvuZcfQzWHzWLWgj5GDXfYLfkl-Nw</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Malík, J</creator><creator>Stulc, T</creator><creator>Wichterle, D</creator><creator>Melenovský, V</creator><creator>Chytilová, E</creator><creator>Lacinová, Z</creator><creator>Marek, J</creator><creator>Ceska, R</creator><general>Institute of Physiology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BYOGL</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20080101</creationdate><title>Hyperlipidemia is associated with altered levels of insulin-like growth factor-I</title><author>Malík, J ; Stulc, T ; Wichterle, D ; Melenovský, V ; Chytilová, E ; Lacinová, Z ; Marek, J ; Ceska, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-4936b42d26b635b08be556a1931e30949b9beaac2e82d664fbdcda10fe261d7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Biomarkers - blood</topic><topic>Case-Control Studies</topic><topic>Cholesterol - blood</topic><topic>Conflicts of interest</topic><topic>Correlation analysis</topic><topic>Diet</topic><topic>Female</topic><topic>Growth hormones</topic><topic>Humans</topic><topic>Hypercholesterolemia - blood</topic><topic>Hyperlipidemias - blood</topic><topic>Independent sample</topic><topic>Insulin-Like Growth Factor Binding Protein 3</topic><topic>Insulin-Like Growth Factor Binding Proteins - blood</topic><topic>Insulin-Like Growth Factor I - analysis</topic><topic>Lipoproteins, HDL - blood</topic><topic>Lipoproteins, LDL - blood</topic><topic>Male</topic><topic>Metabolic syndrome</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Statistical methods</topic><topic>Studies</topic><topic>Triglycerides - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Malík, J</creatorcontrib><creatorcontrib>Stulc, T</creatorcontrib><creatorcontrib>Wichterle, D</creatorcontrib><creatorcontrib>Melenovský, V</creatorcontrib><creatorcontrib>Chytilová, E</creatorcontrib><creatorcontrib>Lacinová, Z</creatorcontrib><creatorcontrib>Marek, J</creatorcontrib><creatorcontrib>Ceska, R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>East Europe, Central Europe Database</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Physiological research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Malík, J</au><au>Stulc, T</au><au>Wichterle, D</au><au>Melenovský, V</au><au>Chytilová, E</au><au>Lacinová, Z</au><au>Marek, J</au><au>Ceska, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyperlipidemia is associated with altered levels of insulin-like growth factor-I</atitle><jtitle>Physiological research</jtitle><addtitle>Physiol Res</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>57</volume><issue>6</issue><spage>919</spage><epage>925</epage><pages>919-925</pages><issn>0862-8408</issn><eissn>1802-9973</eissn><abstract>Previous studies revealed altered levels of the circulating insulin-like growth factor-I (IGF-I) and of its binding protein-3 (IGFBP-3) in subjects with coronary atherosclerosis, metabolic syndrome and premature atherosclerosis. Hyperlipidemia is a powerful risk factor of atherosclerosis. We expected IGF-I and IGFBP-3 alterations in subjects with moderate/severe hyperlipidemia but without any clinical manifestation of atherosclerosis. Total IGF-I and IGFBP-3 were assessed in 56 patients with mixed hyperlipidemia (MHL; cholesterol >6.0 mmol/l, triglycerides >2.0 mmol/l), in 33 patients with isolated hypercholesterolemia (IHC; cholesterol >6.0 mmol/l, triglycerides <2.0 mmol/l), and in 29 healthy controls (cholesterol<6.0 mmol/l, triglycerides<2.0 mmol/l). The molar ratio of IGF-I/IGFBP-3 was used as a measure of free IGF-I. IHC subjects differed from controls by lower total IGF-I (164+/-60 vs. 209+/-73 ng/ml, p=0.01) and IGF-I /IGFBP-3 ratio (0.14+/-0.05 vs. 0.17+/-0.04, p=0.04). Compared to controls, MHL subjects had lower total IGF-I (153+/-54 ng/ml, p=0.0002) and IGFBP-3 (2.8+/-0.6 mg/ml, p<0.0001), but higher IGF-I/IGFBP-3 ratio (0.25+/-0.06, p<0.0001). Differences remained significant after the adjustment for clinical and biochemical covariates, except for triglycerides. Patients with both IHC and MHL have lower total IGF-I compared to controls. The mechanism is presumably different in IHC and MHL. Because of prominent reduction of IGFBP-3 in patients with MHL, they have reduced total IGF-I despite the actual elevation IGF-I/IGFBP-3 ratio as a surrogate of free IGF-I.</abstract><cop>Czech Republic</cop><pub>Institute of Physiology</pub><pmid>18052685</pmid><doi>10.33549/physiolres.931281</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0862-8408 |
| ispartof | Physiological research, 2008-01, Vol.57 (6), p.919-925 |
| issn | 0862-8408 1802-9973 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66654709 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Biomarkers - blood Case-Control Studies Cholesterol - blood Conflicts of interest Correlation analysis Diet Female Growth hormones Humans Hypercholesterolemia - blood Hyperlipidemias - blood Independent sample Insulin-Like Growth Factor Binding Protein 3 Insulin-Like Growth Factor Binding Proteins - blood Insulin-Like Growth Factor I - analysis Lipoproteins, HDL - blood Lipoproteins, LDL - blood Male Metabolic syndrome Middle Aged Mortality Statistical methods Studies Triglycerides - blood |
| title | Hyperlipidemia is associated with altered levels of insulin-like growth factor-I |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T13%3A34%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyperlipidemia%20is%20associated%20with%20altered%20levels%20of%20insulin-like%20growth%20factor-I&rft.jtitle=Physiological%20research&rft.au=Mal%C3%ADk,%20J&rft.date=2008-01-01&rft.volume=57&rft.issue=6&rft.spage=919&rft.epage=925&rft.pages=919-925&rft.issn=0862-8408&rft.eissn=1802-9973&rft_id=info:doi/10.33549/physiolres.931281&rft_dat=%3Cproquest_cross%3E1645052701%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212222432&rft_id=info:pmid/18052685&rfr_iscdi=true |